Pluvicto® is setting a new standard for metastatic prostate cancer care, delivering targeted radiation directly to cancer cells. As one of the few centers nationwide offering this innovative therapy, United Theranostics is dedicated to providing patients with advanced, precision care. Here’s how Pluvicto stands above other treatment options:
Pluvicto: The Future of Prostate Cancer Treatment
Precision
Targeting
Delivers radiation directly to PSMA-positive cancer cells, sparing healthy tissue.
Improved
Survival
38% improvement in overall survival and 60% reduced risk of progression.
Personalized
Care
Combines PSMA PET imaging with therapy for tailored, effective treatment.
Metastic Prostate Cancer
Metastatic prostate cancer occurs when cancer spreads beyond the prostate to areas like the bones or lymph nodes, making treatment options feel limited. That’s where Pluvicto®, a treatment offered by United Theranostics, can help. This advanced radiopharmaceutical therapy targets cancer cells directly, giving you or your loved one the chance for better outcomes and an improved quality of life.
If you’ve been diagnosed with metastatic prostate cancer, we’re here for you. Visit us at one of our outpatient procedure centers to explore cutting-edge care and compassionate support every step of the way. Schedule your consultation today.
Contact us now to take the first step toward advanced treatment.
Delivers radiation directly to PSMA-positive cancer cells while minimizing damage to healthy tissue.
Demonstrated improved overall survival and progression-free survival in clinical trials.
Compared to traditional chemotherapy, Pluvicto is less likely to cause widespread side effects.
Administered in a comfortable outpatient setting with minimal disruption to daily life.
Tailored to patients with PSMA-positive cancer for optimal effectiveness.
Offers multiple doses for sustained treatment impact over time.
The process to begin Pluvicto treatment at United Theranostics is designed to provide you with personalized and effective care. Here’s how it works:
If you’re ready to take the next step, contact United Theranostics to schedule your consultation today. Let us guide you through this innovative treatment journey with care and expertise.
Pluvicto® offers hope for patients with metastatic castration-resistant prostate cancer (mCRPC) by delivering targeted radiation to PSMA-positive cancer cells. It’s designed for individuals who have already explored other therapies and are seeking an innovative option to manage their cancer effectively.
You may be a candidate for Pluvicto if:
Contact United Theranostics today to see if Pluvicto is the right choice for your advanced cancer care.
Pluvicto® is transforming the way metastatic prostate cancer is treated, and United Theranostics is proud to be one of the few centers nationwide offering this advanced radiopharmaceutical therapy. We combine cutting-edge technology, expert care, and a compassionate approach to deliver precision-targeted treatments in a comfortable outpatient setting. From consultation to follow-up, our team guides you every step of the way.
Pluvicto is specifically for patients with advanced prostate cancer who meet the following criteria:
Our team will work closely with you and your referring physician to evaluate your eligibility. We are committed to guiding you through every step of this journey, ensuring clarity and confidence in your treatment plan.
Pluvicto combines a radioactive particle, Lutetium-177, with a PSMA-targeting molecule. The therapy seeks out PSMA proteins in prostate cancer cells, delivering a highly localized dose of radiation that damages the DNA within these cells. This approach minimizes harm to surrounding healthy tissue, offering a more precise and effective treatment option.
Like any cancer therapy, Pluvicto may cause side effects. The most commonly reported include:
Our medical team is here to help you manage these symptoms effectively. We will proactively monitor your health throughout treatment and adjust your care plan as needed.
Because Pluvicto involves radiation, small amounts may pass through bodily fluids (e.g., urine or saliva). To minimize exposure to loved ones:
At United Theranostics, we prioritize education and safety to ensure you and your family feel informed and at ease.
We believe in precision care at every step. During your treatment, we’ll:
This collaborative approach ensures your treatment remains on track and caters to your body and cancer’s needs.
Getting started is simple. You can:
During your consultation, we’ll review your medical history, confirm your PSMA-positive status with a PET scan, and design a treatment plan tailored to your needs.
Coverage for Pluvicto varies depending on your insurance provider. At United Theranostics, we have a dedicated team to:
We are committed to making this life-changing therapy accessible to everyone who needs it.
To keep your loved ones safe, avoid close contact (less than 3 feet) with others for the first two days after treatment. Avoid contact with children and pregnant individuals for seven days. Additionally, it’s recommended to sleep in a separate room from others for at least three days and up to 15 days if your household includes pregnant individuals.
Staying hydrated is key after Pluvicto. Drinking plenty of water helps your body eliminate any residual radioactivity through urine. Frequent urination during the first 24 hours after treatment is encouraged to support this process.
Common side effects include fatigue, dry mouth, nausea, or changes in appetite. You may also notice mild changes in bowel movements or low blood counts. Contact your healthcare provider if you experience severe or prolonged symptoms; they can help manage any concerns.
Most patients can resume regular activities within a few days. Your healthcare team will provide specific instructions based on your health and treatment, but taking it easy during the first few days can help you recover.
